Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALKS 5461 in Treatment Refractory MDD
NCT03188185Phase 3Completed
- Sponsor
- Alkermes
- Start
- Jun 2017
- Primary completion
- Feb 2020
- Modality
- Orthosteric Ligands
- Countries
- 3
01
Overview
A Phase 3 trial of buprenorphine, samidorphan in major depressive disorder (MDD), sponsored by Alkermes. Started Jun 2017; status: completed.
02
Drugs
buprenorphinesamidorphan
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03188185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03188185.